Onesource Specialty

ONESOURCE

Q: How strong is Onesource Specialty balance sheet?

Balance sheet of Onesource Specialty is strong.But short term working capital might become an issue for this company.

Q: Is the debt of Onesource Specialty increasing or decreasing?

Yes, The net debt of Onesource Specialty is increasing.Latest net debt of Onesource Specialty is ₹471 Crs as of Mar-25.This is greater than Mar-24 when it was ₹442 Crs.

Q: Is Onesource Specialty stock expensive?

There is insufficient historical data to gauge this.Latest PE of Onesource Specialty is 0

Price

Small Cap

₹22,188 Cr.

New to Zerodha? Sign-up for free.

Onesource Specialty is in the Healthcare sector with a M.cap of 22188.00 Cr and a PE ratio of 0.0.

Low

1,210

52W Range

High

2,002

Sector PE

27.82

P/B

3.77

Div.Yield

ROE

-98.85%

EBIDTA

70.14

ROCE

-23.64

EPS

8.61

New to Zerodha? Sign-up for free.

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

This data is currently unavailable for this company.

Summary
Profit & Loss
Balance sheet
Cashflow

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

ONESOURCE
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

ONESOURCE
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

Onesource Specialty Pharma Approves Consolidation Of Singapore Business Ops

May 05, 2025

Onesource Specialty Pharma Says Unit 2 Granted GMP Certification By Anvisa

Apr 10, 2025

Onesource Specialty Pharma Gets Tax Adjustment Order Of 425.95 Million Rupees

Mar 13, 2025

Onesource Specialty Pharma Dec-Quarter Consol Loss 688.5 Mln Rupees

Jan 29, 2025

Events:

More Small Cap Ideas

See similar 'Small' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Onesource Specialty do?

Who are the competitors of Onesource Specialty?

Onesource Specialty major competitors are Eris Lifesciences, Concord Biotech, Wockhardt, Astrazeneca Pharma I, Alembic Pharma, Emcure Pharma, Pfizer. Market Cap of Onesource Specialty is ₹22,188 Crs. While the median market cap of its peers are ₹24,461 Crs.

Is Onesource Specialty financially stable compared to its competitors?

Onesource Specialty seems to be less financially stable compared to its competitors. Altman Z score of Onesource Specialty is 14.28 and is ranked 4 out of its 8 competitors.

Does Onesource Specialty pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Onesource Specialty latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Onesource Specialty allocated its funds?

Companies resources are majorly tied in miscellaneous assets

How strong is Onesource Specialty balance sheet?

Balance sheet of Onesource Specialty is strong. But short term working capital might become an issue for this company.

Is the profitablity of Onesource Specialty improving?

Yes, profit is increasing. The profit of Onesource Specialty is -₹49.6 Crs for TTM, -₹391.17 Crs for Mar 2024 and -₹799.83 Crs for Mar 2023.

Is the debt of Onesource Specialty increasing or decreasing?

Yes, The net debt of Onesource Specialty is increasing. Latest net debt of Onesource Specialty is ₹471 Crs as of Mar-25. This is greater than Mar-24 when it was ₹442 Crs.

Is Onesource Specialty stock expensive?

There is insufficient historical data to gauge this. Latest PE of Onesource Specialty is 0

Has the share price of Onesource Specialty grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Onesource Specialty?

Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Onesource Specialty is 34.25% and last quarter promoter holding is 37.77%

Are mutual funds buying/selling Onesource Specialty?

The mutual fund holding of Onesource Specialty is increasing. The current mutual fund holding in Onesource Specialty is 8.32% while previous quarter holding is 4.62%.

ONESOURCE

Share Price

Financials

Revenue mix

Shareholdings

Peers

Forensics

Summary

Profit & Loss

Balance sheet

Cashflow

Product wise

Location wise

Recent events

News

Corporate Actions

Onesource Specialty Pharma Approves Consolidation Of Singapore Business Ops

Onesource Specialty Pharma Says Unit 2 Granted GMP Certification By Anvisa

Onesource Specialty Pharma Gets Tax Adjustment Order Of 425.95 Million Rupees

Onesource Specialty Pharma Dec-Quarter Consol Loss 688.5 Mln Rupees

Events:

Quarterly Results

Quarterly Results

More Small Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Onesource Specialty do?

Who are the competitors of Onesource Specialty?

Is Onesource Specialty financially stable compared to its competitors?

Does Onesource Specialty pay decent dividends?

How has Onesource Specialty allocated its funds?

How strong is Onesource Specialty balance sheet?

Is the profitablity of Onesource Specialty improving?

Is the debt of Onesource Specialty increasing or decreasing?

Is Onesource Specialty stock expensive?

Has the share price of Onesource Specialty grown faster than its competition?

Is the promoter bullish about Onesource Specialty?

Are mutual funds buying/selling Onesource Specialty?